Abstract 19P
Background
Overexpression of CD73 in breast cancer is associated with immunosuppressive, pro-angiogenic tumor microenvironment and with poor patient clinical outcomes. Anti-CD73 antibodies are being investigated in combination with immune checkpoint inhibitors in clinical trials. Here, we investigated the prognostic value of the soluble form of CD73 (sCD73) in patients with advanced triple negative breast cancer (TNBC) treated with first-line durvalumab and chemotherapy, with or without anti-CD73 antibody oleclumab in the randomized, phase II SYNERGY trial (NCT03616886).
Methods
sCD73 levels were measured by ELISA in baseline plasma of 124 patients included in SYNERGY and in 24 healthy donors (HD). We explored association between sCD73 levels and baseline clinical characteristics, treatment response, and survival. Tumor-infiltrating lymphocytes (TILs) were assessed on H&E staining; PD-L1 was analyzed using immunohistochemistry.
Results
TNBC patients had significantly higher baseline sCD73 levels than HD (Mann-Whitney, p<0.001). High baseline levels of sCD73 were associated with liver metastases, high neutrophil-to-lymphocyte ratio (>5), and elevated CA 15-3 at baseline. sCD73 levels showed no association with clinical benefit at 24 weeks or with progression-free survival (PFS). Median overall survival (OS) was significantly shorter in patients with high baseline sCD73 levels compared to those with low sCD73 (18.8 vs. 26.4 months; log-rank, p=0.03). Higher TILs levels correlated with better PFS (log-rank, p=0.04) and OS (log-rank, p=0.03). High PD-L1 expression correlated with better PFS (log-rank, p=0.004). No association was observed between sCD73 levels and TILs or PD-L1 expression. Multivariate analysis (including treatment arm, TILs, PD-L1, sCD73 and disease presentation) confirmed the independent prognostic value of sCD73 (OS; HR=0.5; p=0.02).
Conclusions
In our analysis high baseline sCD73 levels were associated with negative prognostic clinical factors at baseline and with worse OS. The role of sCD73 as independent prognostic factor requires external validation.
Clinical trial identification
NCT03616886; August 6, 2018.
Legal entity responsible for the study
Institut Jules Bordet.
Funding
Institutional grant from AstraZeneca for the clinical trial. Translational analyses were funded by the Association Jules Bordet and the Fondation contre le Cancer (Belgium).
Disclosure
E. Agostinetto: Financial Interests, Personal, Speaker, Consultant, Advisor, Consultancy fee/honoraria: Eli Lilly , Sandoz, AstraZeneca; Financial Interests, Institutional, Research Grant: Gilead; Financial Interests, Personal, Other, Support to attend medical conferences (travel/accommodation/expenses): Novartis, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo. J. Stagg: Financial Interests, Personal, Advisory Board: Surface Oncology, Tarus Therapeutics, Domain Therapeutics, Iteos Therapeutics; Financial Interests, Personal, Stocks/Shares: Surface Oncology; Financial Interests, Institutional, Research Grant: Surface Oncology, Domain Therapeutics. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Vertex, Seattle Genetics, Amgen, INC, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid, Puma; Financial Interests, Personal, Invited Speaker: Eisai, Prime oncology, Teva; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Institutional, Other, Internal speaker: Genentech; Financial Interests, Personal, Other, Regional speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences. L. Buisseret: Financial Interests, Institutional, Advisory Board: Domain Therapeutics; Financial Interests, Institutional, Other, Steering Committee: iTEOS Therapeutics; Financial Interests, Personal, Other, writing of clinical cases: Mirrors of Medicine; Financial Interests, Institutional, Other, Travel grant: Gilead; Financial Interests, Institutional, Research Grant, Research Grant for an investigator initiated trial: AstraZeneca; Non-Financial Interests, Personal, Principal Investigator: iTeos Therapeutics; Non-Financial Interests, Personal, Member: EORTC, BSMO. All other authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display